大肠直肠癌诊断市场－全球产业规模、份额、趋势、机会和预测，按诊断类型（诊断影像、粪便检查、活检等）、按应用、按地区和竞争细分，2020 年至 2030 年

2024 年全球大肠直肠癌诊断市场价值为 180.5 亿美元，预计到 2030 年将达到 237.9 亿美元，预测期内的复合年增长率为 4.85%。全球大肠直肠癌诊断市场正在经历显着增长，这得益于结直肠癌患病率的上升、人们对早期发现的认识的不断提高以及诊断技术的不断进步。大肠直肠癌是全球最常见的癌症之一，早期诊断在改善患者预后和存活率方面发挥关键作用。例如，根据国际癌症研究机构 (IARC) 的数据，2022 年全球诊断出的大肠癌病例超过 190 万例。作为最常见的癌症之一，大肠癌带来了重大的经济和社会挑战。这种日益增长的盛行率凸显了对有效诊断解决方案的需求不断增长，突显了对早期发现和改进筛检方法以应对日益加重的全球疾病负担的迫切需求。

随着医疗保健系统日益重视预防保健和早期检测，对先进诊断工具的需求也持续成长。关键的诊断方法包括大肠镜检查、CT扫描和MRI等影像技术，以及生物标记检测、粪便检测和血液检测。随着人工智慧和机器学习的融合，这些方法正在不断发展，提高了诊断准确性并实现了更早的检测。非侵入式和居家筛检解决方案也越来越受欢迎，因为它们提供了便利性并提高了患者的依从性。

医疗保健提供者，尤其是医院和诊断实验室，是结直肠癌诊断的主要用户，因为他们拥有先进的设备和训练有素的专业人员。然而，随着自我检测试剂盒和行动医疗服务的日益普及，部分需求正转向居家诊断，尤其是在已开发国家。从地理上看，北美和欧洲等已开发地区凭藉其强大的医疗基础设施和较高的筛检率，目前占据市场主导地位，而亚太和拉丁美洲的新兴经济体正在迅速扩张。医疗保健投资的增加、宣传活动的不断推进以及诊断设施可近性的改善，共同推动了这一增长。在技术创新、诊断公司之间的战略合作伙伴关係以及政府推动定期筛检的措施的支持下，大肠直肠癌诊断市场预计将稳步扩张。随着患者认知度的不断提高以及诊断方案的日益普及，预计该市场将在全球对抗大肠直肠癌的斗争中发挥越来越重要的作用。

关键市场驱动因素

大肠直肠癌发生率上升

主要市场挑战

高级诊断成本高昂

主要市场趋势

转向非侵入式和家庭测试

目录

第一章：服务概述

• 市场定义
• 市场范围
  • 覆盖市场
  • 考虑学习的年限
  • 主要市场区隔

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球大肠直肠癌诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依诊断类型（诊断影像、粪便检查、切片、其他）
  • 依用途（医院及专科诊所、门诊护理中心等）
  • 按地区（北美、欧洲、亚太、南美、中东和非洲）
  • 按公司分类（2024）
• 市场地图

第六章：北美大肠癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲大肠癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区大肠直肠癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲

第九章：南美洲大肠癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲大肠直肠癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 阿联酋
  • 沙乌地阿拉伯
  • 南非

第 11 章：市场动态

• 驱动程式
  • 大肠直肠癌发生率上升
  • 镇静的生活方式
  • 研发成长
• 挑战

第 12 章：市场趋势与发展

第 13 章：临床试验分析

第 14 章：竞争格局

• Abbott Laboratories
• Illumina, Inc.
• Sysmex Corporation
• Beckman Coulter
• Siemens Healthineers AG
• Quest Diagnostics
• Danaher Corporation
• Cancer Genetics Inc.
• Biocept Inc.
• Epigenomics AG

第 15 章：策略建议

第 16 章：关于我们与免责声明

Global Colorectal Cancer Diagnostics Market was valued at USD 18.05 billion in 2024 and is expected to reach USD 23.79 billion by 2030 with a CAGR of 4.85% during the forecast period. The global colorectal cancer diagnostics market is witnessing significant growth, driven by a rising prevalence of colorectal cancer, growing awareness about early detection, and continuous advancements in diagnostic technologies. Colorectal cancer ranks among the most commonly diagnosed cancers worldwide, and early diagnosis plays a critical role in improving patient outcomes and survival rates. For instance, according to the International Agency for Research on Cancer (IARC), over 1.9 million colorectal cancer cases were diagnosed worldwide in 2022. As one of the most common cancers, colorectal cancer poses significant economic and societal challenges. This increasing prevalence underscores a rising demand for effective diagnostic solutions, highlighting the urgent need for early detection and improved screening methods to manage the growing global burden of the disease.

As healthcare systems increasingly emphasize preventive care and early detection, the demand for advanced diagnostic tools continues to rise. Key diagnostic methods include imaging techniques such as colonoscopy, CT scans, and MRI, along with biomarker testing, stool-based tests, and blood-based assays. These methods are evolving with the integration of artificial intelligence and machine learning, enhancing diagnostic accuracy and enabling earlier detection. Non-invasive and at-home screening solutions are also gaining popularity, as they offer convenience and improved patient compliance.

Healthcare providers, especially hospitals and diagnostic laboratories, are the primary users of colorectal cancer diagnostics, owing to their access to advanced equipment and trained professionals. However, the growing availability of self-screening kits and mobile health services is shifting some of the demand toward home-based diagnostics, particularly in developed countries. Geographically, while developed regions like North America and Europe currently dominate the market due to their robust healthcare infrastructure and high screening rates, emerging economies in Asia-Pacific and Latin America are rapidly expanding. This growth is fueled by rising healthcare investments, increasing awareness programs, and improving access to diagnostic facilities. The colorectal cancer diagnostics market is set to expand steadily, supported by technological innovations, strategic partnerships among diagnostic firms, and governmental initiatives promoting regular screening. As patient awareness continues to grow and diagnostic options become more accessible, the market is expected to play an increasingly vital role in the global fight against colorectal cancer.

Key Market Drivers

Rising Incidence of Colorectal Cancer

The rising incidence of colorectal cancer is a critical driver of growth in the global colorectal cancer diagnostics market. For instance, in 2023, research from the National Center for Biotechnology Information reported that the incidence of colorectal cancer in Japan was approximately 26.7 per 100,000 men and 22.7 per 100,000 women aged 40 to 44. This highlights the growing prevalence of colorectal cancer in this age group within the country. Colorectal cancer is now one of the most common cancers worldwide, affecting both men and women across diverse age groups. This upward trend is closely linked to changes in lifestyle, including increased consumption of processed foods, sedentary behavior, obesity, alcohol intake, and smoking. The aging global population significantly contributes to the higher prevalence of the disease, as the risk of colorectal cancer increases with age. As the number of cases continues to climb, there is a corresponding surge in demand for early and accurate diagnostic tools. The UK is witnessing an increase in colorectal cancer cases, driven by an aging population, sedentary lifestyles, and changing dietary habits. This highlights the urgent need for comprehensive diagnostic solutions. For instance, Cancer Research UK reports that around 44,100 new bowel cancer cases are diagnosed annually, emphasizing the importance of early detection and effective screening programs. Early detection of colorectal cancer significantly improves prognosis and treatment outcomes. Consequently, healthcare systems across the world are investing more in screening and diagnostic technologies. Colonoscopy remains the gold standard, but there is growing interest in non-invasive tests such as stool-based DNA assays, fecal immunochemical tests (FIT), and blood-based biomarker tests. The increase in cases has also prompted public health authorities to launch nationwide screening programs and awareness campaigns, particularly in developed countries. In emerging economies, rising disease burden and healthcare infrastructure improvements are leading to greater adoption of diagnostic services. This rise in incidence is not just increasing volume demand but also encouraging innovation in diagnostic approaches. Companies are developing faster, more sensitive, and patient-friendly diagnostic solutions, including AI-powered imaging and home-based test kits. Overall, the growing number of colorectal cancer cases globally is fueling advancements and expansions within the diagnostics market, making it a key area of focus for both public and private healthcare stakeholders.

Key Market Challenges

High Cost of Advanced Diagnostics

The high cost of advanced diagnostics remains a significant barrier to the widespread adoption of colorectal cancer screening and detection methods across the globe. While technological innovations such as high-definition colonoscopy, molecular biomarker testing, next-generation sequencing (NGS), and liquid biopsies have significantly improved diagnostic accuracy and patient outcomes, they often come with a high price tag. These costs can be prohibitive for both healthcare providers and patients, particularly in low- and middle-income countries where healthcare resources are limited and out-of-pocket payments are common. Advanced diagnostics typically require sophisticated equipment, skilled personnel, and specialized laboratory infrastructure, all of which contribute to high operational costs. For example, procedures like colonoscopy not only involve expensive imaging devices but also require sedation, trained endoscopists, and post-procedure recovery, adding to the overall expense. Similarly, liquid biopsies and genomic tests demand advanced platforms and reagents, which can drive up costs further. The financial burden can deter individuals from undergoing routine screening, especially in regions without robust public health coverage or insurance systems. As a result, many cases are detected at later stages when treatment is more complex and expensive, ultimately increasing the overall burden on healthcare systems.

To address this challenge, governments and healthcare stakeholders are exploring cost-effective alternatives, such as fecal immunochemical tests (FIT) and stool DNA tests, which offer reasonable sensitivity at a lower cost. The efforts are being made to subsidize testing and expand public screening programs. Despite these efforts, the affordability gap remains a key issue. For the global colorectal cancer diagnostics market to achieve inclusive growth and equitable outcomes, reducing the cost of advanced diagnostics and improving access across socioeconomic groups must become a central focus of future strategies and innovations.

Key Market Trends

Shift Towards Non-Invasive and Home-Based Testin

The global colorectal cancer diagnostics market is witnessing a significant shift towards non-invasive and home-based testing methods, reflecting a broader trend aimed at improving patient comfort, compliance, and early detection rates. Traditional diagnostic procedures like colonoscopy, while effective, are invasive, often uncomfortable, and require specialized medical facilities and trained personnel. These factors have historically limited widespread screening, particularly among populations reluctant to undergo invasive procedures or those with limited access to healthcare centers. Non-invasive tests such as fecal immunochemical tests (FIT), stool DNA assays, and emerging blood-based biomarker tests offer a convenient and less intrusive alternative. These tests can detect early signs of colorectal cancer or precancerous lesions through analysis of stool or blood samples, allowing for easier screening in routine check-ups or even at home. The availability of home-based testing kits has particularly boosted participation in colorectal cancer screening programs by providing privacy, reducing the need for hospital visits, and simplifying sample collection.

This shift is also supported by advancements in molecular biology and biomarker discovery, which have enhanced the sensitivity and specificity of non-invasive tests. Improved diagnostic accuracy helps reduce false positives and negatives, thereby optimizing patient management and follow-up procedures. In developing countries and remote areas, where access to specialized medical facilities is limited, non-invasive and home-based testing has become an essential tool in expanding screening coverage. It also aligns with growing patient preference for minimally disruptive healthcare experiences. The move toward non-invasive and home-based colorectal cancer diagnostics is driving market growth by making early detection more accessible, affordable, and acceptable, ultimately improving outcomes and reducing the global colorectal cancer burden.

Key Market Players

• Abbott Laboratories
• Illumina, Inc.
• Sysmex Corporation
• Beckman Coulter
• Siemens Healthineers AG
• Quest Diagnostics
• Danaher Corporation
• Cancer Genetics Inc.
• Biocept Inc.
• Epigenomics AG

Report Scope:

In this report, the Global Colorectal Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Colorectal Cancer Diagnostics Market, By Diagnosis Type:

• Diagnostics Imaging
• Stool Test
• Biopsy
• Others

Colorectal Cancer Diagnostics Market, By Application:

• Hospitals & Specialty Clinics
• Ambulatory Care Centers
• Others

Colorectal Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Colorectal Cancer Diagnostics Market.

Available Customizations:

Global Colorectal Cancer Diagnostics Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Colorectal Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis Type (Diagnostics Imaging, Stool Test, Biopsy, Others)
    • 5.2.1.1. By Diagnostics Imaging (Sigmoidoscopy, Colonoscopy, and Others)
    • 5.2.1.2. By Stool Test (Guaiac FOBT, Fecal immunochemical (or immunohistochemical) Test (FIT), FIT-DNA Test)
    • 5.2.1.3. By Biopsy (Image Guided Biopsy, Liquid Biopsy, Others)
  • 5.2.2. By Application (Hospitals & Specialty Clinics, Ambulatory Care Centers, and Others)
  • 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle-East and Africa)
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Colorectal Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Colorectal Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Colorectal Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Colorectal Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis Type
      • 6.3.3.2.2. By Application

7. Europe Colorectal Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Colorectal Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Colorectal Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Colorectal Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Colorectal Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Colorectal Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Colorectal Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Colorectal Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Japan Colorectal Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis Type
      • 8.3.2.2.2. By Application
  • 8.3.3. India Colorectal Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Colorectal Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Colorectal Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis Type
      • 8.3.5.2.2. By Application

9. South America Colorectal Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Colorectal Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Colorectal Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Colorectal Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Colorectal Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Colorectal Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Colorectal Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis Type
      • 10.3.2.2.2. By Application
  • 10.3.3. South Africa Colorectal Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis Type
        • 10.3.3.2.1.1. By Application

11. Market Dynamics

• 11.1. Drivers
  • 11.1.1. Increasing Incidence of Colorectal Cancer
  • 11.1.2. Sedative Lifestyle
  • 11.1.3. Growth in Research & Development
• 11.2. Challenges

12. Market Trends & Developments

13. Clinical Trial Analysis

• 13.1. Ongoing Clinical Trials
• 13.2. Completed Clinical Trials
• 13.3. Terminated Clinical Trials
• 13.4. Breakdown of Pipeline, By Development Phase
• 13.5. Breakdown of Pipeline, By Status
• 13.6. Breakdown of Pipeline, By Study Application
• 13.7. Breakdown of Pipeline, By Region
• 13.8. Clinical Trials Heat Map

14. Competitive Landscape

• 14.1. Abbott Laboratories
• 14.2. Illumina, Inc.
• 14.3. Sysmex Corporation
• 14.4. Beckman Coulter
• 14.5. Siemens Healthineers AG
• 14.6. Quest Diagnostics
• 14.7. Danaher Corporation
• 14.8. Cancer Genetics Inc.
• 14.9. Biocept Inc.
• 14.10. Epigenomics AG

15. Strategic Recommendations

16. About Us and Disclaimer